Progress in Acute Myeologenous Leukemia
Experimental and potentially life threatening combination chemotherapy has been used for the induction of remission of acute myelogenous leukaemia (AML) for a little over 10 years. During that time the proportion of patients entering remission has risen from less than a quarter to approaching three-quarters. Furthermore, there is now evidence to suggest that about one-fifth of those now entering remission will remain disease free for more than 3 years and be “at risk for cure”.
KeywordsComplete Remission Acute Myelogenous Leukaemia None None Complete Remission Rate Cytosine Arabinoside
Unable to display preview. Download preview PDF.
- Bell R, Rohatiner AZS, Ford J, Slevin ML, Amess J, Malpas JS, Lister TA (to be published) Short term therapy for acute myelogenous leukaemiaGoogle Scholar
- Ellison RR, Glidewell O (1979) Improved survival in adults with acute myelocytic leukaemia. Proc Am Assoc Cancer Res 20:651Google Scholar
- Keating MJ, Smith TC, McCredie KB (to be published) A four year experience with Anthracycline, Cytosine Arabinoside, Vincristine and Prednisone combination chemotherapy in 325 adults with acute leukaemia. CancerGoogle Scholar
- Priesler H, Browman G, Henderson E, Hryniuk W, Freeman A (1980) Treatment of acute myelocytic leukaemia. Effects of early intensive consolidation. Proc. ASCO 21:C-493Google Scholar
- Rohatiner AZS, Lowes LA, Lister TA (1981) Infection in acute myelogenous leukaemia. An analysis of 168 patients. Journal of Hospital Infection, in pressGoogle Scholar